In the future, a combinational design including anti-CD47 antibody with appropriate chemotherapy and immune-modulating agents such as anti-tumor antibodies, type I IFN, STING agonists, immune checkpoint modulators, and others should be intensely investigated for achieving synergistic and tumor-specific effect for clinical application. This evidence concerns the gene CD47 and neoplasm.